Sign up for free newsletter

 

Signal Capital appoints vice chairman


New York-based Signal Capital Management, a hybrid hedge fund and private equity firm, has appointed Dr. Roger von Hanwehr to its board of directors in the capacity of vice chairman.

Dr. von Hanwehr is the chief executive of Solus, a firm developing energy technologies, and is a co-founder of Arcxeon, a global technology, financial, and strategic consulting firm

He is an internationally recognised authority on biological, chemical and radiological defence; biomedicine; radiosurgery; renewable energy; space based technology; and the application of nanotechnology to these fields.

Dr. von Hanwehr teaches the Biodefense Colloquia in the biotechnology programme at Georgetown University, and is widely published.

He has been an advisor to the IST group at SDIO and BMDO and was a fellow at the Laboratory for Experimental Brain Research of the University of Lund, Sweden, where he specialized in tumour immunoncology, neuroimmunology and neurometabolism.

Dr. von Hanwehr will work with Signal to evaluate investment opportunities globally.

Furtherreading
from Hedgeweek

DTCC adds four to board of directors

Tue 25/04/2017 - 07:52

from our other sites

Sandaire appoints COO

Tue 25/04/2017 - 13:24

Mann joins board of Momentum UK

Tue 25/04/2017 - 13:23

events
6 days 23 hours from now - Abuja
1 week 6 days from now - London
2 weeks 4 days from now - London
2 weeks 5 days from now - San Francisco
training
Mon, 15/05/2017   - London
Mon, 15/05/2017   - London
Mon, 15/05/2017   - London
listingsdirectory
IKONIC Fund Services Ltd.
Tue, 29/11/2016 - 12:28
Backstop Solutions Group
Tue, 08/11/2016 - 18:44
The Gemini Companies
Mon, 17/10/2016 - 12:51
specialreports
other gfm publications